Institute for Research in Biomedicine was established in 2000 with the purpose of progressing the investigation of human immunology, with importance on the tools of host defenses. The work of the research groups now spreads outside immunology to comprise the fields of DNA repair, rare ailments, structural and cell biology.
In India, the Pharmaceutical business of the Institute for Research in Biomedicine focuses on Humanized M-CSF mice, genetically modified non-human animals and methods of use thereof, and genetically modified mice and engraftment.
Institute for Research in Biomedicine filed a patent application numbered 2563/DELNP/2011 that is titled as DENGUE VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF. The patent has been filed in the field of Chemicals. This Patent Application has been granted as Patent Number 349924. This invention covers antibodies and antigen-binding fragments thereof and to cocktails of antibodies and antigen-binding fragments that neutralize dengue virus infection without contributing to the antibody-dependent enhancement of dengue virus infection. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antigen-binding fragments. In addition, the invention relates to the use of the antibodies, antigen-binding fragments, and epitopes in screening methods as well As in the diagnosis and therapy of dengue virus infection.
During the patent examination, the patent examiner raised objections under Section 3(d), 3(e), and 3(i) of the Indian Patents Act, 1970. Under section 3(d) it was pointed out that the invention claimed for a human antibody, or an antigen-binding fragment thereof, that neutralizes a dengue virus, wherein the antibody does not contribute to the antibody-dependent enhancement of dengue virus infection, and in the absence of experiment data, it is unclear whether any unknown technical effect is produced or not. Under section 3(e) the applicant claimed for a pharmaceutical composition comprising two or more human antibodies, or antigen-binding fragments, wherein the antibodies do not contribute to the antibody-dependent enhancement of dengue virus infection, which is just the mere admixture of various compositions with no synergistic effect. Finally, the claims relate to, a therapeutically effective amount of at least one antibody, or antigen-binding fragment thereof, the method including administering the subject a compound for the treatment of the diseases caused by the virus, falling within the scope of section 3 (i)
As a response, the Applicant submitted for the objections raised under sections 3(d), 3(e), and 3(i), the amended claims waive the points raised by the objections, making the present invention allowable.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
